Seres醫療 MCRB 深 滬
已收盤 08-15 16:00:00 美东时间
16.69
-0.170
-1.01%
華盛通- 最 高17.175
- 今 開17.01
- 成交量 5.54万股
- 最 低 16.49
- 昨 收 16.86
- 總市值 1.46亿
- 52周最高 26.40
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 6.53
- 委 比 0.00%
- 總股本 873.24万
- 歷史最高 1040.00
- 量 比 0.45
- 振 幅 4.06%
- 歷史最低 7.20
- 每 手 1
- 風險率 3.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics Reports Q2 Results and Leadership Change
Seres Therapeutics ( ($MCRB) ) has shared an announcement. On August 6, 2025, S...
08-06 19:28
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Uncovering Potential: Seres Therapeutics's Earnings Preview
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings r...
08-06 04:09
Seres Therapeutics announces leadership transition
Seres Therapeutics (NASDAQ:MCRB) appointed Thomas DesRosier and Marella Thorell as co-Chief Executive Officers. This appointment will follow the departure of CEO Eric Shaff on July 31, 2025, after a d...
07-22 19:57
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics announced a conference call and live webcast on August 6, 2025, at 8:30 a.m. ET to discuss Q2 2025 financial results and business updates. The event can be accessed by dialing specific numbers or joining the webcast via the company's website. A replay will be available post-event. Seres, a leader in live biotherapeutics, recently sold VOWST to Nestlé Health Science and is developing SER-155, which has received Breakthrough Ther...
07-22 11:01
Seres Therapeutics Announces Leadership Transition
Seres Therapeutics appoints Thomas DesRosier and Marella Thorell as co-CEO, succeeding Eric Shaff, who steps down but remains on the board. The company is exploring partnerships and deals to secure funding for advancing SER-155, a live biotherapeutic targeting bloodstream infections, and other pipeline assets for inflammatory diseases. The transition highlights Seres' commitment to leveraging leadership expertise and strategic collaborations to d...
07-22 11:00
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Seres Therapeutics announced new exploratory data from its SER-155 Phase 1b study, showing potential benefits in immune reconstitution post allo-HSCT. Results demonstrated higher levels of IL-7 and increased CD4+ T cells in patients treated with SER-155, suggesting its role in enhancing immune recovery and reducing infection risks. The company plans to submit a Phase 2 trial protocol to the FDA and seek partners for further development.
05-27 11:00
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
05-08 20:05
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6
Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price target from $1.25 to $6.
05-08 19:14
Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $0.12 by 3025 percent. This is a 1488.89 percent increase over losses of $(0.27) per share from
05-07 19:03
